PharmaTalkRadio

In this 9 minute webinar, CRAACO® Conference Producer, Andrew Goldstein is joined by Executive Director, Valerie Bowling where they give a summary on what you can expect at the CRAACO: Clinical Research as a Care Option conference.

Embedding clinical research in the care setting can lead to higher rates of clinical trial participation inside of a health system, better health outcomes, lower cost of care and more satisfied patients. CRAACO is a unique opportunity for pharma, healthcare and patients to come together and address how we can build a more integrated research ready platform to improve patient access to clinical trials.

The conference takes place September 12, 2022 at the Westin Copley Place in Boston, MA. For more information please visit www.craacoevent.com

Directors Valerie Bowling and Kate Woda provide a quick overview on what to expect at the 9th annual Mobile Tech in Clinical Trials in under 9 minutes.

Get 10% off with code TEML.

In this podcast, Valerie Bowling, Director of the PODD: Partnership Opportunities in Drug Delivery conference gives a 5 minute overview on what you can expect at the 12th annual PODD taking place October 24-25 at the Westin Copley Place in Boston.

Learn more about the upcoming conference at poddconference.com

Summary:

Join us for an important discussion about the necessity to adjust and adopt media and research strategies to ensure clinical trial recruitment of diverse populations. PharmaTalkRadio’s Valerie Bowling speaks with BBK Worldwide industry experts Justin Jones and Gaby Grekin who will share specific strategies and approaches to apply at the research and media planning stage to achieve more balanced clinical trial representation.

More specifically, our guests discuss:

FDA expectationsStrategic media approaches to create a more diverse and inclusive clinical trial environmentWhat to do before initiating an enrollment or engagement campaignKey considerations for planning and executing an effective outreach campaign that engages and motivates diverse audiencesWhat to prioritize?

This podcast will especially benefit study sponsors, site staff, PIs, CROs/CRAs, designers and planners of clinical studies, as well industry professionals who support these groups to aid in study recruitment and strategy.

Guests:

Justin Jones, Sr Director Media and Content, BBK Worldwide

Gaby Grekin, Sr Director of Global Strategy, BBK Worldwide

Moderator:

Valerie Bowling, Executive Director, PharmaTalkRadio

For more information about patient involvement, engagement and centricity, click here.

Summary:

Join us for an important discussion about the necessity to adjust and adopt media and research strategies to ensure clinical trial recruitment of diverse populations. PharmaTalkRadio’s Valerie Bowling speaks with BBK Worldwide industry experts Justin Jones and Gaby Grekin who will share specific strategies and approaches to apply at the research and media planning stage to achieve more balanced clinical trial representation.

More specifically, our guests discuss:

FDA expectationsStrategic media approaches to create a more diverse and inclusive clinical trial environmentWhat to do before initiating an enrollment or engagement campaignKey considerations for planning and executing an effective outreach campaign that engages and motivates diverse audiencesWhat to prioritize?

 

This podcast will especially benefit study sponsors, site staff, PIs, CROs/CRAs, designers and planners of clinical studies, as well industry professionals who support these groups to aid in study recruitment and strategy.

 

Guests:

Justin Jones, Sr Director Media and Content, BBK Worldwide

Gaby Grekin, Sr Director of Global Strategy, BBK Worldwide

Moderator:

Valerie Bowling, Executive Director, PharmaTalkRadio

 

For more information about patient involvement, engagement and centricity, click here.

About the Episode:

The number of biotech companies out there makes the struggle to find good talent and good outsourcing partners more difficult and more expensive. As a biotech CMO, working with a CRO more worried about delivering their margins than delivering on what you need leads to an insourcing problem of being inappropriately staffed and an outsourcing problem of not being serviced. In this podcast, Joe Arcangelo, Co-founder & Managing Partner, InSeption Group, and Dr Steven Zelenkofske, CMO, SwanBio Therapeutics discuss how the biotech and CRO industries have evolved and how you can identify the best partner for your needs.

Key Takeaways:

How to assess and select outsourcing partnersFocusing on the individuals assigned to your company as opposed to the entire CRODetermining when to outsource and what model to useIntegrating CROs while remaining nimble and flexible as a biotech

About This Episode: 

Dr Derk Arts, Founder and CEO of Castor, lays out what he views as the next phase of data presentation to regulatory agencies, moving away from the standard SDTM (study data tabulation model) into something that more accurately represents the diverse streams of data that are being generated. Potential impacts include: drug approvals based on quality of life, a step forward into precision medicine, and overall increase in patient centricity.

Key Takeaways:

How companies can prepare for a more data-friendly futureWorking groups at the FDA and their involvement in data submission What this direction means for precision medicine, remote monitoring and other innovations in clinical research 

 

 

About the Speaker: 

Derk Arts, MD, PhD, has over fifteen years of experience in medicine, research and technology. He founded Castor to solve the biggest issues in clinical research: a lack of inclusivity, patient focus and impact of data. Castor enables sponsors worldwide to run patient-centric trials on a unified platform that helps them maximize the impact of research data on patient lives.

Dr Derk Arts believes the key to achieving lasting change in the industry is through scalability and standardization. Technology to run better trials and maximize the impact of data should be available to all researchers. 

Over the past 12 months, Castor provided pro-bono support to over 300 COVID-19 trials, and provided the entire infrastructure for the World Health Organizations’ Solidarity Trials.

 

For more information about innovation in clinical research, click here.

COVID-19 changed the clinical research landscape by proving the use and efficacy of DCTs, patient-centricity and adaptive designs. Dr Ubavka DeNoble, Executive Vice President of Biotech Operations and Senior Medical Officer of Parexel Biotech shares advice on how CMOs can think about leadership, change management and investing in new technologies such as artificial intelligence, improved data collection and system interoperability to improve patient recruitment and retention and drug development efficacy.

Key Takeaways:

How to lead with an eye on industry changes and flexibilityThe importance of rewarding innovation rather than standardizing a single approachObservations of successful change management throughout the COVID-19 pandemic

About This Episode: 

What is the future of drug delivery for patients, and how do we get there? 

In this episode, Dr Shawn Davis, who leads the Drug Delivery team of the Biopharmaceuticals Development organization at AstraZeneca, lays out a bold vision discussing how the future of drug delivery is patients interacting less with their disease, and what steps we can take to make that future a reality. 

 

Key Takeaways:

How companies can de-risk drug delivery innovationsHow the current moment in drug delivery is shaping our long-term visionBalancing the competitive landscape, portfolio and patient needs 

 

About the Speaker: 

Shawn Davis, PhD is an Executive Director at AstraZeneca and leads the Drug Delivery team of the Biopharmaceuticals Development organization. The team improves patients’ lives by ensuring AZ’s therapies are as safe, effective, and convenient as possible using technologies that target the delivery of medicines to the site of action and optimizing their effective half-life.  

This requires the evaluation, development, and commercialization of drug delivery technologies across a wide range of modalities in the biopharmaceutical space. Areas of program delivery include: intracellular delivery of nucleic acids, controlled release of antibodies for less frequent dosing, novel routes of administration for therapeutic benefit, and co-delivery of multiple therapeutic molecules. Dr Davis also serves as the CMC leader for early stage assets in the portfolio.

For more information about drug delivery, click here.

About the Episode: 

Creating options for patients with decentralized clinical trials can provide tremendous benefits for certain patients and indications. In this podcast, Labcorp’s Linda Ross, Associate Director of Commercial Strategy, Decentralized Clinical Trials, brings an on-the-ground perspective to the benefit of incorporating decentralized strategies into your clinical trial approach.

Having worked on multiple sides of clinical research, Ms Ross is using her experience running clinical trials via flexible approaches to discuss how, after COVID, the industry can and should continue broader applications of flexible, decentralized clinical trials. 

 

Key Takeaways:

How to convey the value of consistent DCT planning to sponsorsUnderstanding current attitudes and burdens around decentralizationThe next steps in wider adoption of flexible approaches

 

About the Speaker: 

Linda Ross has over 20 years’ experience in the pharmaceutical industry and commenced work with Labcorp in Nov 2008 where she is currently employed as an Ass. Dir. Commercial Strategy, Decentralized Clinical Trials. Linda has worked in a variety of leadership positions across different therapeutic areas that have involved multiple countries in Asia Pacific as well as Americas and Canada. She has developed extensive experience in developing decentralized clinical trials strategies on projects from pre-award, during set up, as well as leading new initiatives for ongoing studies which have been faced with challenging circumstances. 

 

For more information about disruptive innovation in clinical research, click here.